Randomized clinical trials have shown that PI3K/AKT/mTOR inhibitors deliver significant clinical benefits, particularly for patients with advanced hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Here, HR is linked to breast cancer.